CytoMed Therapeutics Ltd (GDTC) Form 6-K — Oct 9, 2026
CytoMed Therapeutics (GDTC) received a Nasdaq deficiency notice on October 6, 2026 because its closing bid price remained below the $1.00 minimum for 30 consecutive business days from August 24 to October 5, 2026. Trading is not immediately affected, and the company has until April 5, 2027 to regain compliance by closing at or above $1.00 for at least 10 consecutive business days.
Key figures
- Cure Condition
- closing bid >= $1.00 for at least 10 consecutive business days
- Deficiency Period
- August 24, 2026 to October 5, 2026 (30 consecutive business days)
- Compliance Deadline
- April 5, 2027 (180 calendar days)
- Minimum Bid Price Requirement Usd
- 1
- Possible Second Compliance Period Days
- 180
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.